Details:

Alternative Title:
MMWR Morb Mortal Wkly Rep
Personal Author:
Serhan, Fatima
Corporate Authors:
Dept of Immunization, Vaccines, and Biologicals ; World Health Organization Regional Office for Africa, Regional Office for the Americas, Regional Office for the Eastern Mediterranean, Regional Office for Europe, Regional Office for South-East Asia, Regional Office for the Western Pacific ; Div of Viral Diseases, National Center for Immunization and Respiratory Diseases and Global Immunization Div, Center for Global Health, CDC
Dept of Immunization, Vaccines, and Biologicals ; World Health Organization Regional Office for Africa, Regional Office for the Americas, Regional Office for the Eastern Mediterranean, Regional Office for Europe, Regional Office for South-East Asia, Regional Office for the Western Pacific ; Div of Viral Diseases, National Center for Immunization and Respiratory Diseases and Global Immunization Div, Center for Global Health, CDC Less -
Description:
In 2001, in anticipation of rotavirus vaccine licensure and introduction, the World Health Organization (WHO) and partners established regional laboratory surveillance networks for rotavirus detection and strain type monitoring among hospitalized children aged <5 years. In 2006, two WHO-prequalified oral rotavirus vaccines were licensed: a 2-dose, single-strain vaccine (Rotarix, GlaxoSmithKline Biologicals) and a 3-dose, multistrain vaccine (RotaTeq, Merck). Both vaccines provide protection against a range of rotavirus strain types, generally classified as G and P types based on specific viral proteins. Based on results of clinical trial data, disease burden data from surveillance networks, and findings from vaccine impact studies, WHO recommends that all countries include rotavirus vaccination in national immunization programs. Vaccination is recommended to help reduce the morbidity and mortality associated with rotavirus, a leading cause of diarrhea in children aged <5 years that was responsible for approximately 450,000 deaths in 2008. This report describes the expansion of the regional rotavirus laboratory surveillance networks to a global surveillance network, the implementation of data quality assurance measures to ensure quality laboratory data reporting to support rotavirus surveillance activities, and data reporting through the surveillance network. Timely, quality surveillance data can provide baseline estimates of rotavirus disease burden to inform decisions regarding rotavirus vaccine introduction in national immunization programs and can help monitor the impact of vaccine introduction on disease trends.
Subject:
[+]
Articles
Capacity Building
Child, Preschool
Global Health
Humans
Immunization Programs
Laboratories
Population Surveillance
Quality Control
Rotavirus
Rotavirus Infections
Rotavirus Vaccines
World Health Organization

Source:
MMWR Morb Mortal Wkly Rep. 2013; 62(20):409-412.
Pubmed ID:
23698607
Pubmed Central ID:
PMC4604939
Document Type:
Journal Article
Collection(s):
Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:
[+]
urn:sha256:283feb8cac6746a82420e4513bd87161a4713fc81c140b7fceea887622149ae1
File Type:

Supporting Files

• 	409-412.nxml	xml
  	409-412f1.gif	gif
  	409-412f1.jpg	jpeg

More +